Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
17.22
Dollar change
-0.19
Percentage change
-1.09
%
IndexRUT P/E17.95 EPS (ttm)0.96 Insider Own1.03% Shs Outstand12.50M Perf Week-2.16%
Market Cap214.73M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.34M Perf Month0.70%
Income12.11M PEG0.90 EPS next Q0.49 Inst Own93.43% Short Float0.48% Perf Quarter4.30%
Sales40.14M P/S5.35 EPS this Y8.38% Inst Trans0.22% Short Ratio5.52 Perf Half Y4.81%
Book/sh22.46 P/B0.77 EPS next Y- ROA3.89% Short Interest0.06M Perf Year-1.20%
Cash/sh0.44 P/C39.04 EPS next 5Y20.00% ROE4.37% 52W Range15.26 - 18.75 Perf YTD-1.77%
Dividend Est.- P/FCF11.82 EPS past 5Y21.40% ROI3.89% 52W High-8.16% Beta0.36
Dividend TTM- Quick Ratio- Sales past 5Y10.79% Gross Margin85.38% 52W Low12.84% ATR (14)0.39
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM-15.69% Oper. Margin41.17% RSI (14)44.86 Volatility2.90% 1.84%
Employees23 Debt/Eq0.11 Sales Y/Y TTM0.85% Profit Margin30.18% Recom1.00 Target Price22.00
Option/ShortNo / Yes LT Debt/Eq0.11 EPS Q/Q-80.92% Payout0.00% Rel Volume0.54 Prev Close17.41
Sales Surprise- EPS Surprise-73.88% Sales Q/Q20.33% EarningsMay 16 BMO Avg Volume10.80K Price17.22
SMA20-1.69% SMA50-0.73% SMA2003.28% Trades Volume5,826 Change-1.09%
May-19-24 08:08AM
May-15-24 10:54PM
04:05PM
Mar-23-24 05:33AM
Mar-21-24 01:53PM
07:00AM Loading…
07:00AM
Jan-23-24 04:05PM
Nov-09-23 07:30AM
Nov-06-23 04:05PM
Oct-30-23 08:00AM
Oct-18-23 08:00AM
Oct-11-23 08:00AM
Oct-03-23 04:05PM
Sep-28-23 06:34PM
Sep-26-23 04:07PM
09:00AM Loading…
Aug-17-23 09:00AM
Aug-09-23 04:05PM
Aug-08-23 08:00AM
Jul-27-23 05:43PM
Jul-17-23 04:05PM
Jun-28-23 04:05PM
May-11-23 09:00AM
07:00AM
May-02-23 04:36PM
Apr-03-23 07:30AM
Mar-31-23 08:00AM
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company offers capital and investments in life science companies, institutions, and inventors. It operates through the Finance Receivables and Pharmaceutical Development segments. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions, and investors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.